RE:RE:RE:RE:RE:RE:re: ' Thank me later' ?.......I HAVE BEEN F***** SCREAMINGRight so once again you make my point, what you offered as guidance is not guidance.
Gilles may have said that a complete collapse of revenue in H1 was "a glitch". I believe he also characterized the failure of a potentially transformative 2 year clinical trial as "A bump in the road"
He can never be trusted to tell shareholders the truth and we just have to wait for Q3 to see how bad it is.